SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient ...
Investing

Praxis study halted for futility, other programs advance

BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...
Clinical Trials Arena on MSN

SEQSTER and Praxis expand collaboration to expedite CNS disorder trials

The collaboration builds on Essential3 for Essential Tremor, extending support to the ENERGY programme.
Benzinga.com

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

On Tuesday, Praxis Precision Medicines Inc. (NASDAQ:PRAX) released topline results for its EMBOLD Phase 2 proof-of-concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic ...
Business Insider

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec.